Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid
decompensation and respiratory failure with elevated inflammatory markers, consistent with …

ABSTRACT BACKGROUND COVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …

Background High levels of serum interleukin-6 (IL-6) correlate with disease severity in
COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) …

Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

Abstract Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …

Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for
COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory …

Importance The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of
people worldwide. Tocilizumab has shown promising results in retrospective studies in …

Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …